Does chemotherapy modify the immune surveillance of hematological malignancies?

Leukemia

Volumn 23, Issue 1, 2009, Pages 53-58

  Barrett, A J ^a   Savani, B N ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Vanderbilt University Transplant Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL LINEAGE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LEUKEMIA; LYMPHOCYTIC INFILTRATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 58249105216     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.273     Document Type: Review

References (58)

1. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909; 5: 273-290.
2. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity (discussion). In: Lawrence HS (ed). Cellullar and Humoral Aspects of the Hyperseisitive States. Hoeber-Harper: New York, NY, USA, 1959, pp 529-532.
3. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360.
5. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994; 5: 91-112.
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
7. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
8. Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM et al Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004; 199: 879-884.
9. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet 2000; 356: 1795-1799.
10. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1-50.
11. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907.
12. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
13. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM et al Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141: 607-614.
14. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117: 821-827.
15. Dolcetti R. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007; 7: 96-101.
16. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1-10.
17. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK et al An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835-843.
18. Franklin J, Tesch H, Hansmann ML, Diehl V. Lymphocyte predominant Hodgkin's disease: Pathology and clinical implication. Ann Oncol 1998; 9 (Suppl 5): S39-S44.
19. EI WA, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y et al T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: Report on 61 patients and review of literature. Leuk Lymphoma 2007; 48: 1764-1773.
20. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/ regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-18543.
21. Ohtani H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7 4.
22. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
23. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
24. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008; 45: 39-48.
25. Barrett AJ. Myelodysplastic syndrome - an example of misguided immune surveillance? Leuk Res 2004; 28: 1123-1124.
26. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005; 174: 8210-8218.
27. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007; 148: 189-198.
28. Molldrem JJ. Vaccination for leukemia. Biol Blood Marrow Transplant 2006; 12: 13-18.
29. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900.
30. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLAA*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization. Clin Cancer Res 2005; 11: 8799-8807.
31. Morita Y, Heike Y, Kawakami M, Miura O, Nakatsuka S, Ebisawa M et al Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer 2006; 119 1360-1367.
32. Einsele H, Ehninger G, Schneider EM, Kruger GF, Vallbracht A, Dopfer R et al. High frequency of graft-versus-host-like syndromes following syngeneic bone marrow transplantation. Transplantation 1988; 45: 579-585.
33. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
34. Gahrton G, Svensson H, Bjorkstrand B, Apperley J, Carlson K, Cavo M et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999; 24: 741-745.
35. Barrett AJ, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS et al Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323-3327.
36. Hess AD, Jones RJ, Morris LE, Noga SJ, Vogelsang GB, Santos GW. Autologous graft-versus-host disease: A novel approach for antitumor immunotherapy. Hum Immunol 1992; 34: 219-224.
37. Lewalle P, Hensel N, Guimaraes A, Couriel D, Jiang YZ, Mavroudis D et al. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: Implications for adoptive immunotherapy with T cells. Br J Haematol 1996; 92: 587-594.
38. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639-647.
39. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
40. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005; 19 507-512.
41. Mustjoki S, Lundan T, Knuutila S, Porkka K. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia 2007; 21: 2363-2368.
42. Mughal TI, Goldman JM. Molecularly targeted treatment of chronic myeloid leukemia: Beyond the imatinib era. Front Biosci 2006; 11: 209-220.
43. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
44. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107: 1688-1695.
45. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1216-1223.
46. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21: 2145-2152.
47. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
48. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol Blood Marrow Transplant 2008; 14: 807-816.
49. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629-633.
50. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM et al Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311-1318.
51. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004; 4: 78-85.
52. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC et al Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006; 20: 29-34.
53. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008; 112: 407-415.
54. Hudson G, Lomas C, Manley S, Caswell M, McDowell H, Pizer B et al. Early lymphocyte regeneration predicts improved survival in childhood acute lymphoblastic leukaemia (abstract). Blood 2003; 102: 1391.
55. Lomas C, Hudson G, Manley S, Caswell M, McDowell H, Pizer B et al. Early lymphocyte regeneration predicts improved survival in childhood acute myeloid leukaemia (abstract). Blood 2003; 102: 3250.
56. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
57. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al Lenalidomide response in relapsed/refractory aggressive non-Hodgkin's lymphoma is related to tumor burden and time from rituximab treatment. ASH Annu Meet Abstr 2007; 110: 2565.
58. Witzig TE, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R et al. Initial results from an international study in relapsed/ refractory aggressive non-Hodgkin's lymphoma to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy. ASH Annu Meet Abstr 2007; 110: 2572.